Spruce Biosciences, Inc. (NASDAQ: SPRB) is a clinical-stage biopharmaceutical company focused on developing enzyme replacement therapies for rare genetic diseases. The company generates no product revenue, operating entirely on capital raised through equity financing while advancing its pipeline toward regulatory approval. Its lead program, TA-ERT, targets mucopolysaccharidosis type IIIB (MPS IIIB), an ultra-rare neurodegenerative disease, with a Biologics License Application (BLA) submission planned for the fourth quarter of 2026 under the FDA's accelerated approval pathway, citing CSF heparan sulfate non-reducing end (CSF HS-NRE) as a reasonably likely surrogate endpoint. If approved, the company intends a potential commercial launch in mid-2027. CEO Javier Szwarcberg, M.D., MPH leads the organization. The company operates within the orphan disease drug development space and is subject to both FDA and EMA regulatory frameworks, with EU orphan designation providing potential market exclusivity protections.

Revenue model

Spruce Biosciences has no approved products and generates no product revenue as of the 10-K filed 2026-03-09. Operations are funded through capital markets financing. Future revenue, if any, would depend on regulatory approval and commercialization of TA-ERT.

Products and services

TA-ERT: an enzyme replacement therapy in clinical development for the treatment of MPS IIIB (mucopolysaccharidosis type IIIB), a rare neurodegenerative lysosomal storage disorder. BLA submission targeted for Q4 2026 under FDA accelerated approval pathway.

Customers and end markets

Target patient population: individuals with MPS IIIB, an ultra-rare pediatric neurodegenerative disease. End markets include rare disease and orphan drug segments in the United States and European Union.

Value-chain role

Clinical-stage drug developer occupying the research, development, and regulatory approval stages of the pharmaceutical value chain. Relies on third-party contract research organizations, clinical trial institutions, and cloud-based infrastructure providers for trial execution and operations.

Geographic exposure

Primary regulatory focus on the United States (FDA) and European Union (EMA). No commercial geographic footprint disclosed as of the 10-K filed 2026-03-09.

Source: SEC 10-K, filed 2026-03-09

Industry: Pharmaceutical Preparations Peers: Jasper Therapeutics Inc Tectonic Therapeutic Inc SAB Biotherapeutics Inc Corvus Pharmaceuticals Inc DiaMedica Therapeutics Inc Vistagen Therapeutics Inc Moleculin Biotech Inc Pasithea Therapeutics Corp Vicapsys Life Sciences, Inc.